Neuren Pharmaceuticals Limited
NURPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1,727,085 | $1,598,835 | $2,731,143 | $3,171,441 |
| - Cash | $5,906 | $3,153 | $2,571 | $17,094 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,721,179 | $1,595,682 | $2,728,572 | $3,154,347 |
| Revenue | $28,277 | $192,505 | $24,327 | $168,999 |
| % Growth | -85.3% | 691.3% | -85.6% | – |
| Gross Profit | $13,380 | $177,424 | $6,438 | $153,337 |
| % Margin | 47.3% | 92.2% | 26.5% | 90.7% |
| EBITDA | $10,908 | $175,108 | $4,075 | $151,096 |
| % Margin | 38.6% | 91% | 16.8% | 89.4% |
| Net Income | $15,031 | $134,027 | $8,016 | $109,276 |
| % Margin | 53.2% | 69.6% | 33% | 64.7% |
| EPS Diluted | 0.12 | 1.03 | 0.061 | 0.83 |
| % Growth | -88.3% | 1,580.3% | -92.6% | – |
| Operating Cash Flow | $128,306 | $9,266 | -$20,536 | $140,047 |
| Capital Expenditures | -$5 | -$7 | -$3 | -$22 |
| Free Cash Flow | $128,301 | $9,259 | -$20,539 | $140,025 |